查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1775440

全球支气管扩张剂市场：2025-2030 年预测

Global Bronchodilator Drug Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球支气管扩张剂市场预计将从 2025 年的 451.11 亿美元成长到 2030 年的 562.75 亿美元，复合年增长率为 4.52%。

本研究报告为寻求市场趋势、竞争格局和成长机会等切实可行的洞察的行业专业人士，提供了关于支气管扩张剂治疗领域不断发展的全面分析。该研究深入探讨了市场结构，并检视了影响其发展轨迹的关键细分市场、地区和最新发展动态。报告涵盖了新冠疫情 (COVID-19) 等全球健康挑战的影响，并详细阐述了市场驱动因素、限制因素和竞争策略。透过关注疾病类型、给药途径和不同地区市场差异等关键领域，本支气管扩张剂市场研究为相关人员提供了驾驭这个复杂而充满活力的行业的宝贵知识。

市场概况和范围

支气管扩张剂市场涵盖缓解气喘和慢性阻塞性肺病(COPD) 等呼吸系统疾病引起的气道阻塞的治疗方法。本研究透过分析疾病类型（气喘、COPD 等）和给药途径（口服、注射、剂量、吸入）等关键细分市场来定义市场。研究也评估了北美、欧洲、亚太、南美以及中东和非洲等主要地区的市场动态。支气管扩张剂市场显示，呼吸系统疾病盛行率的上升、药物输送系统的进步以及医疗保健投资的增加是推动其成长的因素，而监管挑战和学名药的竞争则是限制因素。

调查方法

该调查方法严格结合了来自行业相关人员的原始数据以及来自监管文件、临床试验和市场报告的二手数据。此外，我们也透过专家咨询检验假设，以确保准确性。该研究整合了波特五力模型和产业价值链分析，旨在提供市场竞争力和商业框架的整体情况。

市场动态

研究指出，吸入器和生技药品的日益普及是市场的主要驱动力，这得益于其功效和患者依从性。然而，高昂的研发成本和严格的生技药品要求也构成了限制因素。竞争对手之间的竞争非常激烈，领先的企业纷纷投资于新型疗法并建立策略联盟以维持市场占有率。产业价值链分析强调了原料供应商、製造商和经销商在确保产品供应方面的关键作用。

市场区隔分析

支气管扩张剂市场根据疾病类型和给药途径进行细分。气喘和慢性阻塞性肺病 (COPD) 因其高发病率而占据疾病类型细分市场的主导地位，而吸入式药物因其靶向给药和快速起效而占据给药途径细分市场的主导地位。按地区划分，受先进的医疗基础设施和高疾病负担的推动，北美占据最大份额；而亚太地区则因人们意识的提高和医疗可及性的改善而呈现快速增长。

竞争格局与分析

支气管扩张剂市场竞争激烈，葛兰素史克、阿斯特捷利康和诺华等主要企业尤其突出。近期发展凸显了这些公司为加强其产品组合所采取的策略性倡议。例如，葛兰素史克已在多个地区扩大其用于治疗 COPD 的三重吸入复合剂 Trelegy Ellipta 的核准，从而加强了其市场渗透率。同样，阿斯特捷利康用于治疗重度气喘的生物製药Fasenra 也有新的临床数据显示其具有抑制气喘发作的功效，使其成为气喘领域的有力竞争者。此类创新凸显了对个人化治疗和联合治疗的关注。该研究还检视了维罗纳製药等新创新兴企业，该公司正在开髮用于治疗 COPD 的安西芬特林雾化疗法，并可能透过新的作用机制颠覆市场。透过供应商竞争矩阵检验，併购和联盟（例如诺华的数位健康整合合作伙伴关係）进一步加剧了竞争。

公司简介

罗氏公司、吉利德科学公司、默克、辉瑞和雅培等主要企业的详细资料，有助于深入了解其策略、产品平臺和市场定位。这些公司简介重点介绍了公司如何利用研发、监管核准和地理扩张来维持支气管扩张剂市场的成长。

本报告的主要优点

  • 深刻分析：获得深入的市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场，涵盖主要地区和新兴地区。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2024 年的实际数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略与市场占有率分析
  • 收益成长和预测细分市场和区域分析（包括国家）
  • 公司概况（策略、产品、财务、主要发展等）

目录

第一章 引言

  • 市场概览
  • COVID-19的影响
  • 市场定义
  • 市场区隔

第二章调查方法

  • 调查数据
  • 先决条件

第三章执行摘要

  • 调查重点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 业内竞争对手之间的竞争
  • 产业价值链分析

第五章全球支气管扩张剂市场依疾病类型分析

  • 介绍
  • 气喘
  • 慢性阻塞性肺病（COPD）
  • 其他的

6. 全球支气管扩张剂市场依给药途径分析

  • 介绍
  • 口服
  • 注射
  • 吸入器

7. 全球支气管扩张剂市场区域分析

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 以色列
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 印度
    • 泰国
    • 台湾
    • 印尼
    • 其他的

第八章竞争格局及分析

  • 主要企业和策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第九章 公司简介

  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • Novartis AG
  • Verona Pharma plc
  • Pfizer Inc.
  • Abbott
  • AstraZeneca plc
简介目录
Product Code: KSI061613440

The Global Bronchodilator Drug Market is expected to grow from USD 45.111 billion in 2025 to USD 56.275 billion in 2030, at a CAGR of 4.52%.

The Global Bronchodilator Drug Market study provides a comprehensive analysis of the evolving landscape of bronchodilator therapies, targeting industry experts seeking actionable insights into market trends, competitive dynamics, and growth opportunities. This research delves into the market's structure, examining key segments, geographic regions, and recent developments that shape its trajectory. The study addresses the impact of global health challenges, such as COVID-19, and offers a detailed perspective on market drivers, restraints, and competitive strategies. By focusing on critical areas like disease types, administration routes, and regional market variations, the Global Bronchodilator Drug Market study equips stakeholders with the knowledge to navigate this complex and dynamic industry.

Market Overview and Scope

The bronchodilator drug market encompasses therapies designed to relieve airway obstruction in respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). The study defines the market by analyzing key segments, including disease types (asthma, COPD, and others) and routes of administration (oral, injection, debate, and inhaler). It also evaluates the market dynamics across major regions, such as North America, Europe, Asia Pacific, South America, and the Middle East and Africa. The Global Bronchodilator Drug Market highlights how rising prevalence of respiratory diseases, advancements in drug delivery systems, and increasing healthcare investments drive growth, while regulatory challenges and generic competition pose restraints.

Research Methodology

The research employs a rigorous methodology, combining primary data from industry stakeholders with secondary data from regulatory filings, clinical studies, and market reports. Assumptions are validated through expert consultations to ensure accuracy. The study integrates Porter's Five Forces and industry value chain analyses to provide a holistic view of market competitiveness and operational frameworks.

Market Dynamics

The study identifies the growing adoption of inhaler devices and biologics as key market drivers, fueled by their efficacy and patient compliance. However, high R&D expenses and stringent regulatory requirements act as restraints. The competitive rivalry is intense, with major players investing in novel therapies and strategic collaborations to maintain market share. The industry value chain analysis reveals the critical roles of raw material suppliers, manufacturers, and distributors in ensuring product availability.

Market Segmentation Analysis

The Global Bronchodilator Drug Market segments the market by disease type and administration route. Asthma and COPD dominate the disease type segment due to their high prevalence, while inhalers lead the administration route segment for their targeted delivery and rapid onset. Geographically, North America holds the largest share, driven by advanced healthcare infrastructure and high disease burden, while Asia Pacific exhibits the fastest growth due to rising awareness and improving access to care.

Competitive Environment and Analysis

The Global Bronchodilator Drug Market study emphasizes the competitive landscape, spotlighting key players such as GlaxoSmithKline plc, AstraZeneca plc, and Novartis AG. Recent developments highlight strategic moves by these companies to strengthen their portfolios. For instance, GlaxoSmithKline has advanced its triple-therapy inhaler, Trelegy Ellipta, with expanded approvals in multiple regions for COPD management, enhancing its market penetration. Similarly, AstraZeneca's Fasenra, a biologic for severe asthma, has gained traction through new clinical data demonstrating its efficacy in reducing exacerbations, positioning it as a competitive alternative in the asthma segment. These innovations underscore the focus on personalized therapies and combination treatments. The study also examines emerging players like Verona Pharma, which is progressing its ensifentrine nebulized therapy for COPD, potentially disrupting the market with a novel mechanism of action. Mergers, acquisitions, and collaborations, such as Novartis' partnerships for digital health integration, further intensify competition, as analyzed through the vendor competitiveness matrix.

Company Profiles

Detailed profiles of major players, including F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Merck & Co., Inc., Pfizer Inc., and Abbott, provide insights into their strategies, product pipelines, and market positioning. These profiles highlight how companies leverage R&D, regulatory approvals, and geographic expansion to sustain growth in the Global Bronchodilator Drug Market.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation

By Disease Type

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

By Route of Administration

  • Oral
  • Injection
  • Inhaler

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Overview
  • 1.2. COVID-19 Impact
  • 1.3. Market Definition
  • 1.4. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Bronchodilator Drug Market Analysis, By Disease Type

  • 5.1. Introduction
  • 5.2. Asthma
  • 5.3. Chronic Obstructive Pulmonary Disease (COPD)
  • 5.4. Others

6. Global Bronchodilator Drug Market Analysis, By Route of Administration

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Injection
  • 6.4. Inhaler

7. Global Bronchodilator Drug Market Analysis, By Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. UAE
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. South Korea
    • 7.6.4. India
    • 7.6.5. Thailand
    • 7.6.6. Taiwan
    • 7.6.7. Indonesia
    • 7.6.8. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. F. Hoffmann-La Roche Ltd
  • 9.2. Gilead Sciences, Inc.
  • 9.3. GlaxoSmithKline plc.
  • 9.4. Merck & Co., Inc.
  • 9.5. Novartis AG
  • 9.6. Verona Pharma plc
  • 9.7. Pfizer Inc.
  • 9.8. Abbott
  • 9.9. AstraZeneca plc